Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIHAL E ABDULLA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1750585345
CMS profile
79323
Location
LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,857.85

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,073.08 192
Consulting Fee $250.00 1
Honoraria $200.00 1
Long term medical supply or device loan $199.40 2
Education $135.37 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $502.59 15
Novartis Pharmaceuticals Corporation $309.93 8
Amgen Inc. $308.28 15
PFIZER INC. $250.93 18
ModernaTX, Inc. $250.00 1
Merck Sharp & Dohme LLC $244.27 14
Pharmacyclics LLC, an AbbVie Company $234.59 6
Incyte Corporation $219.01 13
Celgene Corporation $217.80 12
Novocure GmbH $200.00 1
AstraZeneca Pharmaceuticals LP $194.48 10
Heron Therapeutics, Inc. $163.32 1
Bayer HealthCare Pharmaceuticals Inc. $136.62 7
E.R. Squibb & Sons, L.L.C. $125.58 13
Lilly USA, LLC $122.09 5
Seagen Inc. $105.81 4
GENZYME CORPORATION $90.67 3
Genentech USA, Inc. $80.47 3
PUMA BIOTECHNOLOGY, INC. $77.39 3
EISAI INC. $61.42 3
Kite Pharma, Inc. $57.65 3
Karyopharm Therapeutics Inc. $56.14 2
Blueprint Medicines Corporation $54.46 2
Takeda Pharmaceuticals U.S.A., Inc. $53.23 2
GlaxoSmithKline, LLC. $53.09 3
ABBVIE INC. $48.77 2
AVEO Pharmaceuticals, Inc. $47.69 2
Myovant Sciences Inc. $45.58 2
ARRAY BIOPHARMA INC $44.89 2
SERVIER PHARMACEUTICALS LLC $44.60 2
Organon LLC $42.06 3
Gilead Sciences, Inc. $41.07 2
Astellas Pharma US Inc $40.94 2
JAZZ PHARMACEUTICALS INC. $37.84 1
Global Blood Therapeutics, Inc. $34.98 2
Regeneron Healthcare Solutions, Inc. $33.60 1
Exelixis Inc. $25.98 1
EMD Serono, Inc. $24.16 1
MorphoSys, US Inc. $23.89 1
Alexion Pharmaceuticals, Inc. $21.40 1
Coherus Biosciences Inc. $21.13 1
Daiichi Sankyo Inc. $19.56 1
EUSA Pharma (US) LLC $19.33 1
Boehringer Ingelheim Pharmaceuticals, Inc. $19.14 1
Stemline Therapeutics Inc. $18.34 1
Ipsen Biopharmaceuticals, Inc $17.93 1
Rigel Pharmaceuticals, Inc. $15.15 1

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIHAL E ABDULLA

NPI 1750585345 · CMS profile ID 79323

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750585345?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750585345?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750585345?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1750585345?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $4,857.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $15.8710/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914782919 CMS
Celgene Corporation $26.1910/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932509821 CMS
Gilead Sciences, Inc. $22.0010/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929597301 CMS
Celgene Corporation $17.0009/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932509819 CMS
Incyte Corporation $20.2409/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008669 CMS
Incyte Corporation $1.7809/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008671 CMS
AstraZeneca Pharmaceuticals LP $22.1309/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915855807 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.6209/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929824491 CMS
Lilly USA, LLC $15.0809/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918257591 CMS
Amgen Inc. $8.6109/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939853501 CMS
Janssen Biotech, Inc. $29.6209/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885553361 CMS
AstraZeneca Pharmaceuticals LP $16.2709/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914832117 CMS
Pharmacyclics LLC, an AbbVie Company $25.0009/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890335659 CMS
Kite Pharma, Inc. $20.4109/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065937 CMS
Amgen Inc. $30.2209/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939227665 CMS
Pharmacyclics LLC, an AbbVie Company $28.1209/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890335657 CMS
E.R. Squibb & Sons, L.L.C. $0.3409/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932509803 CMS
E.R. Squibb & Sons, L.L.C. $9.4609/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932509807 CMS
PFIZER INC. $3.2509/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949346545 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.1309/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955578045 CMS
PFIZER INC. $21.6809/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949311877 CMS
Amgen Inc. $13.1309/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939227663 CMS
AstraZeneca Pharmaceuticals LP $22.2409/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915676977 CMS
Karyopharm Therapeutics Inc. $28.7609/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946525663 CMS
Novartis Pharmaceuticals Corporation $15.4609/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893483207 CMS
Celgene Corporation $20.0209/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932509795 CMS
Merck Sharp & Dohme LLC $21.7908/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944666545 CMS
Amgen Inc. $28.2008/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939227661 CMS
PFIZER INC. $4.6808/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949226509 CMS
Amgen Inc. $21.5308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939853499 CMS
Organon LLC $11.9508/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946417867 CMS
PFIZER INC. $2.3708/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949249357 CMS
Incyte Corporation $3.0308/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008655 CMS
Incyte Corporation $13.6308/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008657 CMS
Regeneron Healthcare Solutions, Inc. $33.6008/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094943 CMS
Incyte Corporation $21.7108/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008663 CMS
Novartis Pharmaceuticals Corporation $7.0608/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893483205 CMS
Lilly USA, LLC $29.4308/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918188453 CMS
Gilead Sciences, Inc. $19.0708/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929597299 CMS
Amgen Inc. $27.8408/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939853507 CMS
EMD Serono, Inc. $24.1608/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941545929 CMS
ARRAY BIOPHARMA INC $22.5208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949351315 CMS
AstraZeneca Pharmaceuticals LP $19.1007/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914954953 CMS
Incyte Corporation $12.8707/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008647 CMS
Merck Sharp & Dohme LLC $14.1407/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944666461 CMS
Seagen Inc. $25.1807/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904093899 CMS
Merck Sharp & Dohme LLC $24.4107/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944698163 CMS
Novartis Pharmaceuticals Corporation $22.7907/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893483203 CMS
Amgen Inc. $22.3407/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939853497 CMS
GlaxoSmithKline, LLC. $21.0907/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944737451 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,341.74 117
PY2020 $2,704.13 119
PY2021 $9,081.32 150
PY2022 $4,857.85 199
PY2023 $7,918.86 255
PY2024 $9,911.15 275
PY2025 $9,150.41 262

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,514,624.98 147
PY2024 Principal investigator $1,076,950.03 67
PY2023 Principal investigator $497,917.11 20
PY2022 Principal investigator $375,809.84 7
PY2021 Recipient $480.95 1
PY2021 Principal investigator $100,502.71 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

147 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $134,320.64 12/31/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923502
Principal investigator 1 Merck Sharp & Dohme LLC $5,665.24 12/31/2025 Non-covered Recipient Entity
Cancer Blood and Specialty Clinic
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927787
Principal investigator 1 Merck Sharp & Dohme LLC $27,784.63 12/31/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta No dispute reported 06/30/2026 1232928894
Principal investigator 1 PFIZER INC. $5,796.24 12/31/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228750990
Principal investigator 1 PFIZER INC. $1,958.18 12/27/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228725392
Principal investigator 1 Janssen Research & Development, LLC $11,861.00 12/22/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175436582
Principal investigator 1 Janssen Research & Development, LLC $19,324.00 12/19/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib No dispute reported 06/30/2026 1175436575
Principal investigator 1 PFIZER INC. $343,803.60 12/19/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715879
Principal investigator 1 PFIZER INC. $22.50 12/19/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716057
Principal investigator 1 PFIZER INC. $37.50 12/17/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716063
Principal investigator 1 Merck Sharp & Dohme LLC $2,000.00 12/15/2025 Non-covered Recipient Entity
Cancer Blood and Specialty Clinic
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927743
Principal investigator 1 PFIZER INC. $18,693.22 12/13/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228745054
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 12/10/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337097
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 12/10/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337103
Principal investigator 1 BeOne Medicines Ltd. $6,990.00 12/09/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190328243
Principal investigator 1 PFIZER INC. $15.00 12/09/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716155
Principal investigator 1 PFIZER INC. $3,916.36 11/26/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228723734
Principal investigator 1 Janssen Research & Development, LLC $7,500.00 11/24/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1175436749
Principal investigator 1 Genentech, Inc. $7,329.00 11/20/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211582862
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 11/18/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330165
Principal investigator 1 PFIZER INC. $22.50 11/18/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716059
Principal investigator 1 PFIZER INC. $1,690.88 11/05/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228737322
Principal investigator 1 Janssen Research & Development, LLC $5,259.00 11/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib No dispute reported 06/30/2026 1175436786
Principal investigator 1 PFIZER INC. $53,894.01 10/31/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228741066
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 10/21/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336789
Principal investigator 1 PFIZER INC. $7,640.05 10/15/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715713
Principal investigator 1 PFIZER INC. $91,680.90 10/15/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716151
Principal investigator 1 PFIZER INC. $45,840.45 10/14/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716153
Principal investigator 1 PFIZER INC. $7.50 10/14/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716339
Principal investigator 1 Janssen Research & Development, LLC $490.00 10/13/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib No dispute reported 06/30/2026 1175436698
Principal investigator 1 PFIZER INC. $37.50 10/13/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715881
Principal investigator 1 PFIZER INC. $114,601.20 10/13/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715977
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,666.18 10/10/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185549485
Principal investigator 1 PFIZER INC. $11,095.68 10/09/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228756855
Principal investigator 1 Janssen Research & Development, LLC $19,961.00 10/06/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib No dispute reported 06/30/2026 1175436839
Principal investigator 1 BeOne Medicines Ltd. $6,212.00 09/30/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190328239
Principal investigator 1 PFIZER INC. $21,894.34 09/24/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228750032
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 09/23/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336881
Principal investigator 1 Janssen Research & Development, LLC $4,387.00 09/22/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436449
Principal investigator 1 Janssen Research & Development, LLC $8,392.00 09/22/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436681
Principal investigator 1 Genentech, Inc. $7,929.00 09/17/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211582857
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 09/16/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336911
Principal investigator 1 Janssen Research & Development, LLC $20,898.00 09/04/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436378
Principal investigator 1 Merck Sharp & Dohme LLC $66,582.76 08/31/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232924344
Principal investigator 1 Merck Sharp & Dohme LLC $43,191.60 08/31/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta No dispute reported 06/30/2026 1232928896
Principal investigator 1 PFIZER INC. $4,390.88 08/29/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228765955
Principal investigator 1 PFIZER INC. $114,601.20 08/26/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715709
Principal investigator 1 PFIZER INC. $60.00 08/26/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715883
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 08/20/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342207
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 08/20/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342212
Principal investigator 1 BeOne Medicines Ltd. $7,801.00 08/19/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190328237
Principal investigator 1 PFIZER INC. $57,300.60 08/15/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715885
Principal investigator 1 PFIZER INC. $5,063.18 07/31/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228772521
Principal investigator 1 BeOne Medicines Ltd. $17,654.00 07/22/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190328241
Principal investigator 1 PFIZER INC. $114,601.20 07/22/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715979
Principal investigator 1 PFIZER INC. $45,840.45 07/22/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715983
Principal investigator 1 PFIZER INC. $22.50 07/22/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716061
Principal investigator 1 PFIZER INC. $15.00 07/10/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715981
Principal investigator 1 Merck Sharp & Dohme LLC $17,500.00 07/07/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta No dispute reported 06/30/2026 1232928692
Principal investigator 1 Janssen Research & Development, LLC $240.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436500
Principal investigator 1 Janssen Research & Development, LLC $21,353.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1175436609
Principal investigator 1 Janssen Research & Development, LLC $10,975.00 06/30/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436730
Principal investigator 1 BeOne Medicines Ltd. $25,838.16 06/26/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342278
Principal investigator 1 PFIZER INC. $22,536.00 06/26/2025 Non-covered Recipient Entity
Cancer and Blood Research Center LLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228792298
Principal investigator 1 Janssen Research & Development, LLC $4,571.00 06/23/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436644
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 06/12/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337006
Principal investigator 1 BeOne Medicines Ltd. $1,879.04 06/12/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337012
Principal investigator 1 Janssen Research & Development, LLC $240.00 06/12/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436546
Principal investigator 1 Janssen Research & Development, LLC $362.00 06/12/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436558
Principal investigator 1 BeOne Medicines Ltd. $1,879.04 06/11/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337042
Principal investigator 1 Genentech, Inc. $7,756.00 06/11/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211582846
Principal investigator 1 Janssen Research & Development, LLC $19,516.00 06/09/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1175436367
Principal investigator 1 Genentech, Inc. $24,469.60 06/03/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582866
Principal investigator 1 Janssen Research & Development, LLC $4,394.00 05/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436455
Principal investigator 1 PFIZER INC. $57,300.60 05/27/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228723878
Principal investigator 1 PFIZER INC. $15.00 05/27/2025 Non-covered Recipient Entity
Cancer and Blood Research Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228761186
Principal investigator 1 Janssen Research & Development, LLC $3,753.00 05/26/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1175436554
Principal investigator 1 BeiGene, Ltd. $20,633.00 05/20/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325116
Principal investigator 1 BeiGene, Ltd. $1,439.81 05/15/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323544
Principal investigator 1 BeiGene, Ltd. $4,697.60 05/15/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323546
Principal investigator 1 BeiGene, Ltd. $15,720.00 05/12/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323556
Principal investigator 1 ABBVIE INC. $5,498.55 05/07/2025 Non-covered Recipient Entity
CANCER BLOOD AND SPECIALTY CLINIC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202482445
Principal investigator 1 Janssen Research & Development, LLC $11,536.00 05/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436563
Principal investigator 1 Janssen Research & Development, LLC $4,256.00 05/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436597
Principal investigator 1 Janssen Research & Development, LLC $5,616.00 05/05/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436726
Principal investigator 1 BeiGene, Ltd. $2,625.00 04/29/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323064
Principal investigator 1 Genentech, Inc. $5,354.00 04/29/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582895
Principal investigator 1 BeiGene, Ltd. $1,439.81 04/17/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323588
Principal investigator 1 BeiGene, Ltd. $1,879.04 04/17/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323590
Principal investigator 1 BeiGene, Ltd. $9,395.20 04/17/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323592
Principal investigator 1 Genentech, Inc. $482.00 04/15/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582886
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,490.70 04/09/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185549483
Principal investigator 1 BeiGene, Ltd. $9,985.00 04/08/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325118
Principal investigator 1 Mirati Therapeutics, Inc. $3,481.40 04/04/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531223
Principal investigator 1 BeiGene, Ltd. $9,395.20 04/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321890
Principal investigator 1 Janssen Research & Development, LLC $1,275.00 03/31/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175436417
Principal investigator 1 Janssen Research & Development, LLC $5,390.00 03/31/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436569
Principal investigator 1 Genentech, Inc. $1,684.00 03/26/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582890
Principal investigator 1 BeiGene, Ltd. $4,697.60 03/24/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321900
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/24/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321902
Principal investigator 1 BeiGene, Ltd. $1,439.81 03/24/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321904
Principal investigator 1 BeiGene, Ltd. $8,612.72 03/24/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321906
Principal investigator 1 BeiGene, Ltd. $1,879.04 03/24/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321908
Principal investigator 1 Genmab U.S., Inc. $3,450.00 03/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929981
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 03/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1175436477
Principal investigator 1 Mirati Therapeutics, Inc. $10,920.00 03/19/2025 Non-covered Recipient Entity
Cancer And Blood Specialty Clinic
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236531218
Principal investigator 1 Janssen Research & Development, LLC $4,066.00 03/10/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436372
Principal investigator 1 Janssen Research & Development, LLC $1,335.00 03/10/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436792
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325264
Principal investigator 1 BeiGene, Ltd. $4,319.43 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325266
Principal investigator 1 BeiGene, Ltd. $8,612.72 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325268
Principal investigator 1 BeiGene, Ltd. $939.52 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325278
Principal investigator 1 BeiGene, Ltd. $939.52 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325280
Principal investigator 1 BeiGene, Ltd. $4,697.60 03/03/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325282
Principal investigator 1 Janssen Research & Development, LLC $14,309.00 03/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436593
Principal investigator 1 BeiGene, Ltd. $31,440.00 02/27/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325286
Principal investigator 1 BeiGene, Ltd. $4,319.43 02/27/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325288
Principal investigator 1 BeiGene, Ltd. $25,838.16 02/27/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325290
Principal investigator 1 BeiGene, Ltd. $7,516.16 02/27/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325292
Principal investigator 1 BeiGene, Ltd. $14,092.80 02/27/2025 Non-covered Recipient Entity
Cancer and Blood Specialty Clinic - Los Alamitos
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325294
Principal investigator 1 Genmab U.S., Inc. $1,100.00 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929953
Principal investigator 1 Genmab U.S., Inc. $4,667.00 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929956
Principal investigator 1 Genmab U.S., Inc. $2,000.00 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929964
Principal investigator 1 Genmab U.S., Inc. $4,716.40 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929971
Principal investigator 1 Genmab U.S., Inc. $1,041.70 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929974
Principal investigator 1 Genmab U.S., Inc. $2,850.00 02/20/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929985
Principal investigator 1 Janssen Research & Development, LLC $310.00 02/19/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436533
Principal investigator 1 Janssen Research & Development, LLC $4,392.00 02/19/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436816
Principal investigator 1 AstraZeneca UK Limited $38,585.70 02/14/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185549481
Principal investigator 1 Genentech, Inc. $480.30 02/14/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582870
Principal investigator 1 Genentech, Inc. $8,955.00 02/14/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582882
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,665.10 02/12/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185549479
Principal investigator 1 Janssen Research & Development, LLC $26,442.00 02/03/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436520
Principal investigator 1 Janssen Research & Development, LLC $50,500.00 01/31/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175436736
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,323.89 01/29/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LLC
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185549487
Principal investigator 1 Genentech, Inc. $9,022.00 01/28/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211582849
Principal investigator 1 Genentech, Inc. $66,490.00 01/23/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582874
Principal investigator 1 Genentech, Inc. $3,588.00 01/23/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211582878
Principal investigator 1 Genentech, Inc. $18,157.00 01/22/2025 Non-covered Recipient Entity
CANCER + BLOOD RESEARCH CENTER LLC
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211582854
Principal investigator 1 Genmab U.S., Inc. $700.00 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929949
Principal investigator 1 Genmab U.S., Inc. $19,613.10 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929960
Principal investigator 1 Genmab U.S., Inc. $7,998.90 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929968
Principal investigator 1 Genmab U.S., Inc. $1,050.00 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929978
Principal investigator 1 Genmab U.S., Inc. $6,567.10 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD SPECIALTY CLINIC
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235929988
Principal investigator 1 Janssen Research & Development, LLC $4,449.00 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436361
Principal investigator 1 Janssen Research & Development, LLC $5,147.00 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436588
Principal investigator 1 Janssen Research & Development, LLC $399.00 01/16/2025 Non-covered Recipient Entity
CANCER AND BLOOD RESEARCH CENTER LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175436709